Background:This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients.Materials and Methods:Patients were randomly assigned to D 30 mg m 2 as intravenous infusion (i.v.) and EPI 30 mg m 2 i.v. every week (D/EPI arm), or D 70 mg m 2 i.v. every 3 weeks and oral P 5 mg twice daily (D/P arm). Chemotherapy was administered until disease progression or unacceptable toxicity.Results:A total of 72 patients were enrolled in the study and randomly assigned to treatment: 37 to D/EPI and 35 to D/P. The median progression-free survival (PFS) was 11.1 months (95% CI 9.2-12.6 months) in the D/EPI arm and 7.7 months (95% CI 5.7-9.4 months) in the D/P arm (P0.0002). The median survival was 27.3 months (95% CI 22.1-30.8 months) in the D/EPI arm and 19.8 months (95% CI 14.4-24.8 months) in the D/P arm (P0.003). Both regimens were generally well tolerated.Conclusion:The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P. © 2011 Cancer Research UK. All rights reserved.

Petrioli, R., Pascucci, A., Conca, R., Chiriacò, G., Francini, E., Bargagli, G., et al. (2011). Doxetacel and epirubicin compared with doxetacel and prednisone in advanced castrate-resistant prostate cancer: a randomized phase II study. BRITISH JOURNAL OF CANCER, 104(4), 613-619 [10.1038/bjc.2011.5].

Doxetacel and epirubicin compared with doxetacel and prednisone in advanced castrate-resistant prostate cancer: a randomized phase II study

Fiaschi A. I.;Ponchietti R.;Francini G.
2011-01-01

Abstract

Background:This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients.Materials and Methods:Patients were randomly assigned to D 30 mg m 2 as intravenous infusion (i.v.) and EPI 30 mg m 2 i.v. every week (D/EPI arm), or D 70 mg m 2 i.v. every 3 weeks and oral P 5 mg twice daily (D/P arm). Chemotherapy was administered until disease progression or unacceptable toxicity.Results:A total of 72 patients were enrolled in the study and randomly assigned to treatment: 37 to D/EPI and 35 to D/P. The median progression-free survival (PFS) was 11.1 months (95% CI 9.2-12.6 months) in the D/EPI arm and 7.7 months (95% CI 5.7-9.4 months) in the D/P arm (P0.0002). The median survival was 27.3 months (95% CI 22.1-30.8 months) in the D/EPI arm and 19.8 months (95% CI 14.4-24.8 months) in the D/P arm (P0.003). Both regimens were generally well tolerated.Conclusion:The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P. © 2011 Cancer Research UK. All rights reserved.
Petrioli, R., Pascucci, A., Conca, R., Chiriacò, G., Francini, E., Bargagli, G., et al. (2011). Doxetacel and epirubicin compared with doxetacel and prednisone in advanced castrate-resistant prostate cancer: a randomized phase II study. BRITISH JOURNAL OF CANCER, 104(4), 613-619 [10.1038/bjc.2011.5].
File in questo prodotto:
File Dimensione Formato  
docetaxel.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 322.29 kB
Formato Adobe PDF
322.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/23855